TCF25 Regulates Lysosomal Adaptation and Cell Death in Glucose Starvation

Study Background and Research Question

Cellular adaptation to nutrient deprivation is fundamental to survival, particularly in conditions such as cancer, ischemia, and metabolic disorders. Glucose, serving as the principal source of ATP and biosynthetic precursors, is tightly regulated. Under glucose starvation, cells activate catabolic pathways—most notably autophagy—to maintain energy homeostasis. While transient adaptation supports survival, prolonged deprivation can result in cell death, contributing to tissue injury and pathology. However, the precise mechanisms governing the switch between adaptation and cell death during metabolic stress remain incompletely understood (Ren et al., 2025).

Key Innovation from the Reference Study

The study by Ren et al. addresses this gap by identifying Transcription Factor 25 (TCF25) as a central nutrient sensor that governs both metabolic adaptation and lysosome-dependent cell death (LDCD) under glucose starvation. Using a genome-wide CRISPR-Cas9 loss-of-function screen, the authors pinpointed TCF25 as a critical regulator of glucose-starvation-induced cell death, revealing a previously uncharacterized link between lysosomal acidification, ferritinophagy, and cell fate decisions. This work provides a mechanistic bridge between nutrient sensing, autophagy, and regulated cell death pathways, with implications for targeting metabolic vulnerabilities in disease contexts (Ren et al., 2025).

Methods and Experimental Design Insights

Ren et al. implemented a genome-wide CRISPR-Cas9 knockout screen in mammalian cells subjected to glucose starvation, enabling unbiased identification of genes required for cell death under these conditions. The screen revealed an enrichment of lysosomal pathway genes, with particular focus on TCF25. Functional validation involved gene knockout and overexpression studies, assessment of lysosomal acidification (via fluorescent probes), autophagy flux assays, and measurements of lysosomal membrane permeability (LMP). Key mechanistic interrogation included the use of pharmacological inhibitors and genetic modulation of V-ATPase, the proton pump that acidifies lysosomes. In vivo relevance was established using a mouse model of hepatic ischemia-reperfusion injury (IRI), comparing outcomes in TCF25-deficient versus wild-type animals (Ren et al., 2025).

Core Findings and Why They Matter

• TCF25 is Essential for Cell Death under Glucose Starvation: Loss of TCF25 confers significant resistance to glucose-starvation-induced cell death, whereas its expression promotes susceptibility (Ren et al., 2025).
• TCF25 Drives Lysosomal Acidification via V-ATPase: Mechanistic experiments demonstrate that TCF25 enhances V-ATPase expression and activity, resulting in increased lysosomal acidification—a prerequisite for efficient autophagy and catabolic adaptation under nutrient stress.
• Prolonged Glucose Starvation Triggers TCF25-Dependent Ferritinophagy and Cell Death: While early autophagic responses are cytoprotective, extended glucose deprivation leads to TCF25-mediated ferritinophagy (degradation of ferritin to release iron), which in turn increases lysosomal membrane permeability and triggers lysosome-dependent cell death (LDCD).
• In Vivo Protection in TCF25-Deficient Mice: Genetic deletion of TCF25 in mice protects hepatic tissue from ischemia-reperfusion-induced injury, highlighting the pathophysiological relevance of this pathway (Ren et al., 2025).

These findings elucidate how TCF25 acts as a metabolic switch, balancing adaptation and death via modulation of lysosomal function. The identification of TCF25 as a master regulator suggests new therapeutic targets for conditions characterized by metabolic and oxidative stress, including cancer and ischemia.

Comparison with Existing Internal Articles

Recent internal resources have highlighted the role of iron metabolism and lysosomal function in cancer biology and iron-overload disorders. For example, "Iron Chelation at the Crossroads: Strategic Insights for ..." (read more) discusses how iron chelators, such as Deferasirox, can exploit iron-dependent vulnerabilities in tumor cells, linking iron homeostasis to regulated cell death pathways, including ferroptosis and lysosomal stress. Similarly, "Deferasirox: Novel Insights into Iron Chelation and Tumor..." (read more) explores how targeting iron metabolism with oral iron chelators can inhibit tumor growth and modulate apoptotic responses.

Ren et al.'s findings complement these perspectives by demonstrating that lysosomal ferritinophagy and acidification, regulated by TCF25, are key determinants of cell fate under metabolic stress. This mechanistic overlap suggests that interventions targeting iron release and lysosomal homeostasis—such as the use of iron chelators—could be leveraged to modulate LDCD in cancer and ischemia.

Limitations and Transferability

While the study provides compelling evidence for TCF25's role in cell death during glucose starvation, several limitations warrant consideration. Most experiments were conducted in immortalized cell lines and murine models, which may not fully capture human disease heterogeneity. The translational relevance to specific cancer subtypes or ischemic pathologies requires further validation. Moreover, the precise regulatory networks upstream and downstream of TCF25, including potential crosstalk with other nutrient sensors (e.g., AMPK, mTOR), remain to be elucidated. As with many lysosome-focused interventions, potential off-target effects and tissue-specific responses must be carefully evaluated before clinical translation (Ren et al., 2025).

Protocol Parameters

• CRISPR-Cas9 screen | genome-wide library | identification of nutrient sensors | unbiased gene discovery in glucose starvation | paper
• Glucose starvation assay | 0–1 mM glucose | induction of metabolic stress | mimics tumor microenvironment or ischemia | paper
• Lysosomal acidification probe | LysoTracker, pH-sensitive dyes | quantification of acidification | assesses lysosomal function under stress | paper
• Iron chelation intervention | 3–20 μM Deferasirox | in vitro modulation of iron-dependent cell death | recommended for autophagy/LDCD workflows | workflow_recommendation
• Mouse hepatic IRI model | TCF25 knockout vs wild-type | in vivo validation of metabolic adaptation | links nutrient sensing to tissue injury | paper

Why this cross-domain matters, maturity, and limitations

The intersection of iron metabolism, lysosomal biology, and nutrient sensing is increasingly recognized as a therapeutic target in both cancer and ischemic diseases. The mechanistic link established by Ren et al.—that TCF25-driven ferritinophagy governs susceptibility to LDCD—parallels strategies used in cancer research to target iron-dependent cell death (such as ferroptosis) and disrupt tumor growth (internal article). However, while the foundational biology is robust, direct clinical translation requires further investigation, particularly regarding off-target effects, optimal dosing, and disease-specific contexts.

Research Support Resources

Researchers aiming to study iron metabolism, lysosomal function, or cell death pathways in the context of metabolic stress can utilize Deferasirox (SKU A8639), a well-characterized oral iron chelator, to modulate iron availability and investigate ferritinophagy or lysosomal cell death mechanisms in vitro (typical concentrations: 3–20 μM; soluble in DMSO or ethanol; refer to workflow recommendations and product specifications for protocol optimization; source: product_spec). Deferasirox is suitable for experiments examining inhibition of iron uptake from transferrin, apoptosis induction via caspase-3 activation, and inhibition of tumor growth by iron chelation strategies. For deeper mechanistic context, the internal articles linked above provide guidance on integrating iron chelation into advanced cancer and metabolic research workflows.